Post-operative pain (residual pain, any severity) · adults (> 18 years of age) with trigger finger
NSAID injection showed no clear difference in residual pain compared with glucocorticoid injection (low certainty).
1 finding from 1 review
Global assessment of treatment success · adults (> 18 years of age) with trigger finger
NSAID injection showed no clear difference in participant‐reported treatment success compared with glucocorticoid injection (low certainty).
1 finding from 1 review
Adverse events · adults (> 18 years of age) with trigger finger
It is very uncertain whether NSAID injection changes adverse events compared with glucocorticoid injection (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with shoulder pain
1 finding from 1 review
Function Various validated function scales. · Patients with shoulder pain
1 finding from 1 review
Participant‐assessed success 50% improvement on numerical rating 0 to 10 scale for pain) · Patients with shoulder pain
It is very uncertain whether ultrasound‐guided injection changes participant‐assessed success 50% improvement on numerical rating 0… compared with non‐image‐guided injection (very low certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · Patients with shoulder pain
1 finding from 1 review
Number of adverse events · Patients with shoulder pain
Ultrasound‐guided injection showed no clear difference in number of adverse events compared with non‐image‐guided injection (low certainty).
1 finding from 1 review
Serious adverse events Not reported · Patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
VISA‐A (score 0 to 100; 100 = no problems) After 3 months (6 to 12 months) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
Summary of findings: Injection therapies showed no clear difference in VISA‐A (score 0 to 100; 100 = no problems) At 6 weeks compared with placebo or no injection control (low certainty).
3 findings from 1 review
MD 0.79
5 studies · 200 participants
Low
no estimate extracted
5 studies · 189 participants
Low
MD 0.14
3 studies · 132 participants
Low
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Pain (VAS; score 0 to 100; 0 = no pain) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes pain (VAS; score 0 to 100; 0 = no pain) compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Return to sports At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes return to sports At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Patient satisfaction Number of satisfied patients · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes patient satisfaction (number of participants satisfied with their… compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).
3 findings from 1 review
Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
3 findings from 1 review
Change in level of needlestick injuries · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Change in slope of needlestick injuries · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Intravascular injection · Adult patients undergoing hand, wrist or forearm surgery
Multiple showed no clear difference in intravascular injection compared with single‐injection technique (moderate certainty).
1 finding from 1 review